Invited Speakers

Dr. Ana Denis-Bacelar

Dr. Ana Denis-Bacelar is a Principal Scientist at the National Physical Laboratory since 2017, the UK’s National Metrology Institute, working towards the provision of traceable, accurate and reproducible measurement capabilities in nuclear medicine, where she leads the dosimetry for radiopharmaceuticals technical area. She studied a Licentiate Degree in Physics focused on particle physics at the University of Santiago de Compostela in Spain and then moved to the UK, where she obtained a PhD in experimental nuclear physics at the University of Brighton in 2011. She then moved scientific fields into nuclear medicine clinical research, with a postdoctoral research fellowship at The Institute of Cancer Research working with the Royal Marsden Hospital in London until 2017, working towards the provision of evidence for the need of personalised dosimetry-based treatments. She is actively involved in various research projects like the European EURAMET on-going AlphaMet and former MRTDosimetry projects, focusing on providing end-to-end metrology support for the safe and effective implementation of dosimetry-guided molecular radiotherapy. She is the current chair of the EANM Physics Committee, a former member of EFOMP SIG_FRID’s Steering Committee, and also participate in the EARL Working Group on quantitative SPECT harmonisation for ¹⁷⁷Lu.

Dr. Marco Brambilla

Marco Brambilla received a degree in Physics (1988) from the University of Milan, Italy, a post degree diploma in Medical Physics (1993) from the University of Milan, Italy and a post degree diploma in Health Statistics (1997) from the University of Milan, Italy.

He is currently head of the Medical Physics Department of the University Hospital of Novara and 6 General Hospitals in Piedmont, Italy

He served as Secretary General, President and past-president of EFOMP in the years 2012-2022. He was chairing the European School for Medical Physics Experts in the years 2016-2018. In the 2024 he was awarded with the EFOMP Honorary membership.

In the last 30 years he had experience in nuclear medicine, computed tomography, interventional cardiology and radiology. Since 20 years he is the Radiation Protection Expert for the University Hospital of Novara and 6 regional General Hospitals.

Since 2007, an International Atomic Energy Agency (IAEA) expert sent in many missions organised by the IAEA.

He is currently teaching as Professor to BSC Radiographers, Faculty of Medicine, University of East Piedmont and in the Specialization in Medical Physics, University of Turin (2003-today). He is currently serving, since the first edition in 2016, as vice Director in a master program of the University of Eastern Piedmont on “Radioactive waste management”.

The research activities cover different aspects of medical physics: nuclear medicine instrumentation, estimation of dose from diagnostic X-ray examinations, radiation protection of patients, statistics in medicine.

He is author/co-author of more than 150 articles/book chapters (H-index:36). He is currently senior editor for British Journal of Radiology and associate editor for Physica Medica – European Journal of Medical Physics.

Prof. Katarina Sjögreen Gleisner

Katarina Sjögreen Gleisner (female), Full professor, received her PhD in Medical Radiation Physics in 2001, with a thesis oriented to image processing and analysis with applications in radionuclide therapy. During 2001 – 2011 she worked in parallel as clinical medical physicist and in academia, as funded PI. In 2011 she received position as senior lecturer at the Medical Radiation Physics, and in 2017 obtained full professorship at the Faculty of Science, Lund University. Currently she is director of studies in medical physics at Lund university, has teaching duties and is supervisor for several PhD students and MSc projects enrolled in medical physics and oncology. She maintains her research in radionuclide therapy dosimetry, in close collaboration with clinical oncologists, and acts as responsible physicist in clinical trials. Sjögreen Gleisner is a former member of the Dosimetry committee of the European Association of Nuclear Medicine (EANM), was member of the ICRU Report Committee 31 on Treatment Planning for Radiopharmaceutical Therapy, and in a working group within the IAEA. She has published ~80 publications/reports/book chapters. Sjögreen Gleisner has been granted research grants from the EU (under Euramet), the Swedish Research Council, the Swedish Cancer foundation, and the Swedish Radiation Protection Authority.

Dr. Lidia Strigari

Dr. Lidia Strigari (female), PhD, is Head of the Department of Medical Physics at the IRCCS Azienda Ospedaliero-Universitaria di Bologna [University Hospital and Research Center], Bologna, Italy. She received her Specialization in Medical Physics in 2002 and her PhD in Advanced Technologies in Biomedicine in 2014. Since 2019, she has led clinical and translational research in radiotherapy, molecular radiotherapy, radioembolization, artificial intelligence, and clinical radiobiology. She is actively involved as Principal Investigator and collaborator in national and international projects (EU4Health, IHI, COST, NATO), focusing on innovative radiation-based therapies, artificial intelligence, and radiobiology. She has authored over 312 articles in indexed, peer-reviewed journals (Scopus h-index: 39), 12 book chapters, and holds two international patents. She is a former member of the Dosimetry Committee of the European Association of Nuclear Medicine (EANM), served on the ICRU Report Committee 31 on Treatment Planning for Radiopharmaceutical Therapy, and was part of the EANM Radiobiology Group. She currently leads two focus groups under the EFOMP SIG-FRIG umbrella. Dr. Strigari regularly serves as reviewer for international journals and as faculty and invited speaker at national and international scientific events. She is also responsible for postgraduate education in medical physics at her institution, supervising PhD students and medical physics residents.

Dr. Marta Cremonesi

Marta Cremonesi graduated in Physics at the University of Milano (1993), subsequently receiving Medical Physics Specialization (1997). She has been working as a Medical Physicist in the European Institute of Oncology (Milan, Italy), since 1994, in the Nuclear Medicine Department up to 201, then as Director in the Radiation Research Unit of the Medical Imaging and Radiation Sciences Department.

She gained experience in nuclear medicine imaging and quantification, radiation protection, radio-guided surgery, internal dosimetry and risk-benefit analysis for radionuclide therapy. Her research has been addressing dosimetry and optimisation of innovative therapies with radiopharmaceuticals, dose-effect correlations, radiobiological models, and personalized patient care.

She has been Member of the EANM Dosimetry Committee from 2020 to 2024. She is collaborating in several international working groups within EANM, EFOMP (SIGFRID), AIFM (Associazione Italiana Fisica in Medicina), and COST actions, addressing various topics of Molecular radiotherapy – among which pharmacokinetic models, internal dosimetry software, dose-effect correlations, innovative radiopharmaceuticals, alpha dosimetry, bone marrow dosimetry, recommendations and guide lines.

She is active in Education, teaching Internal Dosimetry at the Specialization School of Medical Physics at the University of Milano, being also Supervisor of Master in Physics, Medical Physics Specialization, and PhD theses for universities of Italy and other European countries.

She has been invited speaker at more than 80 International Congresses and Workshops. She published more than 170 peer-reviewed papers and 15 book chapters. H-index 48 (Scopus).

Dr. Julia Brosch-Lenz

Dr. Julia Brosch-Lenz is a passionate medical physicist with a strong interest in dosimetry to provide patients with optimum treatment. Her educational background includes a Bachelor (B.Sc.), a Master (M.Sc.), and a Doctoral (Dr.rer.nat.) degree in Medical Physics from Ludwig Maximilian University of Munich, Germany, where she gained comprehensive knowledge in nuclear medicine theranostics (i.e., therapy and imaging), radiation safety, and dosimetry. Her research focusses on image-based dosimetry for internal radionuclide therapies towards accurate, reproducible, and practical absorbed dose estimation at the organ, voxel- and microscopic level. She has more than six years of clinical experience working as a medical physicist expert in Germany, which provided her with valuable insights into the clinical routine of nuclear medicine imaging and therapy. During a post-doctoral fellowship at the BC Cancer Research Institute, Vancouver, BC, Canada, she continued to work on dosimetry and focused on reducing the variability within the dosimetry calculation workflow. In her current role at the Institute of Nuclear Medicine, Bethesda, MD, USA, she aims to continue her research towards treatment personalization by using theranostic imaging data.

Dr. Christina Zacharatou

Dr. Christina Zacharatou received her PhD in Experimental High Energy Physics in 2001 and her MSc in Medical Physics in 2005 from Lund University in Sweden. She completed her studies in Boston as a Postdoctoral Fellow at Massachusetts General Hospital and Harvard Medical School in 2007.

Since then, she has worked as a clinical Medical Physicist in radiation therapy in Denmark and France, holding positions at Rigshospitalet, Copenhagen; Institut Curie, Paris and Institut Bergonié, Bordeaux.

Christina is currently a Senior Medical Physicist at St Luke’s Radiation Oncology Network in Dublin and an Adjunct Associate Professor at the Centre for Physics in Health and Medicine of University College Dublin.

She is also contributing to the work of EFOMP as a member of the Science Committee and chair of the Joint EFOMP/ESTRO/EANM/ESR WG Software as a Medical Device.

Christina’s interests include software development, treatment planning, radiobiology and proton therapy.

Prof. Manuel Bardiès

Manuel Bardiès obtained his Doctorate on radiopharmaceutical dosimetry from Toulouse University, France in 1991. He has been developing his research in radiopharmaceutical dosimetry within INSERM (National Institute of Health and Medical Research) since 1992 in Nantes, then in Toulouse (2011), and in Montpellier since 2021.

Manuel Bardiès was one of the founders of the EANM Dosimetry Committee (member from 2001 to 2013, chair 2009-2011). He chaired the EFOMP Science Committee between 2014 and 2016, and is the convenor and the current chair of the EFOMP Special Interest Group for radionuclide internal dosimetry

The group led by Manuel Bardiès is primarily involved in radiopharmaceutical dosimetry, at various scales (cell, tissue, organ). This requires the ability to assess radiopharmaceutical pharmacokinetics in vivo, through quantitative SPECT or PET small-animal imaging or in the clinics. An important part of the research activity involves Monte Carlo modelling of radiation transport. The objective is to improve molecular radiotherapy by promoting patient-specific treatments (personalized medicine).

Francesco Cicone (EANM)

Francesco Cicone graduated from the Medical School of “Sapienza” University of Rome in 2008, where he completed his specialty training in Nuclear Medicine in 2014. Between 2006 and 2014 he carried out international research fellowships in Ghent (BE), Lausanne (CH), London (UK) and Jülich (GE). In August 2012 he obtained the Post-Graduate Certificate in Nuclear Medicine: Science and Practice from King’s College London, UK. Between 2015 and 2019 he worked at the University Hospital of Lausanne (CH) as a Research Fellow within the frame of the Horizon 2020 Marie Curie Innovative Training Network MEDICIS-PROMED. In 2018, he obtained a PhD degree in “Angio-Cardio-Thoracic Physiopathology and Imaging” from “Sapienza” University of Rome. In January 2023 he obtained the degree of PhD in Life Sciences from the University of Lausanne (Switzerland) discussing a thesis titled: “Development of novel radiolabeled peptides and proteins: mouse and human radiation dosimetry”.

He is Associate Professor of Diagnostic Imaging and Radiotherapy at the “Magna Graecia” University of Catanzaro (IT). He is also consultant in Nuclear Medicine at the “Mater Domini” University Hospital of Catanzaro, and at the PET/MRI service of the Research Centre in Neuroscience of “Magna Graecia” University of Catanzaro.

He currently serves as Secretary and vice-chair of the EANM Dosimetry Committee. He is also a member of the European Association of Neuro Oncology (EANO), of the European Organization for Research and Treatment of Cancer (EORTC) Imaging Group and of the EORTC Brain Tumor Group (BTG), including membership of the BTG Imaging and Nuclear Medicine Committees.

Prof. Peter Covens

Peter Covens is a certified radiation protection expert and head of the radiation protection department of the Vrije Universiteit Brussel (VUB). He teaches radiation protection, nuclear measurement techniques and accelerator applications at VUB and is also research professor at the Molecular Imaging and Therapy research group of VUB where he focusses on preclinical dosimetry and dosimetry aspects in radiobiology related to targeted alpha therapy.

Peter Covens has a background in engineering, nuclear physics, accelerator physics and radiation protection dosimetry with a wide expertise in nuclear measurement techniques, radioactive waste management and various radiation protection issues related to medical applications. He is a former member of the EANM radiation protection committee and a current member of the EURADOS working group 13 – Dosimetry in Nuclear Medicine.

Adam Kesner (SNMMI)

Dr. Adam Kesner is a board-certified medical physicist serving as both a clinical and research physicist at Memorial Sloan Kettering Cancer Center in New York, where he is an Attending Physicist and Deputy Service Chief of Molecular and X-ray Imaging Physics. He earned his Ph.D. in Biomedical Physics and has trained and worked across five countries, gaining deep expertise in nuclear medicine imaging, radiopharmaceutical therapy, and data-driven technologies. Dr. Kesner began his career in PET instrumentation and quantitative imaging, developing novel methods to improve motion correction and image quality.

He also leads efforts to modernize data stewardship in medical imaging, strengthening the infrastructure that connects imaging instrumentation, dosimetry, and clinical decision-making. His current research focuses on developing accessible, standardized tools for internal dosimetry to support precision treatment planning. He is a member of the SNMMI MIRD Committee and a lead driver of the MIRDsoft initiative, which provides free, open-access software tools for the nuclear medicine community.

Jessica Clements (AAPM)

Jessica Clements is a medical physicist and radiation safety officer at the University of Vermont Medical Center. She earned her BS in physics from Pittsburg State University in 2002 and her MS in nuclear engineering sciences from the University of Florida in 2005. She was certified by the American Board of Radiology in diagnostic radiologic physics in 2008 and nuclear medical physics in 2011. She specializes in clinical medical physics and radiation safety officer, serving as RSO of large health care systems for most of her career. 

She has served in many capacities within AAPM, ACR, ABR, and CRCPD and was named a fellow of the AAPM in 2018 and the ACR in 2023. Currently, she chairs the new Radiopharmaceutical Committee within the AAPM Science Council, Task Group 313 on nuclear medicine shielding requirements, and helped to organize the 2023 AAPM summer school on radiopharmaceutical therapy.

Robert Hobbs (AAPM)

Dr. Robert Hobbs is an Associate Professor and Medical Physicist in the Department of Radiation Oncology at Johns Hopkins and holds secondary appointment in the departments of Radiology (Nuclear Medicine) and Medical Oncology. Dr. Hobbs earned his undergraduate degrees in physics from the Université Louis Pasteur in Strasbourg, France and his Ph.D. from the University of New Mexico in high energy physics.

His major work has been to develop a dosimetric methodology for targeted alpha-particle radiopharmaceutical therapy specific to the short range and high LET of alpha-emitters. Dr. Hobbs has served as an elected member of the MIRD Committee, is the chairman of the AAPM Radiopharmaceutical Therapy sub-Committee, and serves on a number of committees and task groups that further the development, use, and education of radiopharmaceutical therapy and dosimetry for a wide range of national and international organizations. Most recently he has been awarded the 2025 MIRD Loevinger-Berman award.